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Abstract
Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well
recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process
in many patients is driven by an immunoglobulin E (IgE)-dependent process. Mast cell activation and
release of mediators, in response to allergen and IgE, results in a cascade response, culminating in
B lymphocyte, T lymphocyte, eosinophil, fibroblast, smooth muscle cell and endothelial activation.
This complex cellular interaction, release of cytokines, chemokines and growth factors and
inflammatory remodeling of the airways leads to chronic asthma. A subset of patients develops
severe airway disease which can be extremely morbid and even fatal. While many treatments are
available for asthma, it is still a chronic and incurable disease, characterized by exacerbation,
hospitalizations and associated adverse effects of medications. Omalizumab is a new option for
chronic asthma that acts by binding to and inhibiting the effects of IgE, thereby interfering with one
aspect of the asthma cascade reviewed earlier. This is a humanized monoclonal antibody against IgE
that has been shown to have many beneficial effects in asthma. Use of omalizumab may be
influenced by the cost of the medication and some reported adverse effects including the rare
possibility of anaphylaxis. When used in selected cases and carefully, omalizumab provides a very
important tool in disease management. It has been shown to have additional effects in urticaria,
angioedema, latex allergy and food allergy, but the data is limited and the indications far from clear.
In addition to decreasing exacerbations, it has a steroid sparing role and hence may decrease
adverse effects in some patients on high-dose glucocorticoids. Studies have shown improvement in
quality of life measures in asthma following the administration of omalizumab, but the effects on
pulmonary function are surprisingly small, suggesting a disconnect between pulmonary function,
exacerbations and quality of life. Anaphylaxis may occur rarely with this agent and appropriate
precautions have been recommended by the Food and Drug Administration (FDA). As currently
practiced and as suggested by the new asthma guidelines, this biological agent is indicated in
moderate or severe persistent allergic asthma (steps 5 and 6).
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Introduction
Asthma is a chronic inflammatory airway disease charac-
terized by infiltration of the mucosa by inflammatory
cells, mucus hypersecretion, subbasement membrane
fibrosis, smooth muscle hypertrophy, epithelial loss and
alterations of angiogenesis [1]. The result of these changes
is airway obstruction, a cumulative effect of airway
inflammation and remodeling changes. These various
definitions are summarized in Table 1. Inflammatory
processes that occur in asthma are summarized in Table 2.
Several inflammatory events occur in asthma, resulting in
the observed pathophysiological (Figure 1) and clinical
effects [1-3]. Th2-type T cells secreting a distinctive set of
cytokines [such as interleukin (IL)-4, IL-5 and IL-13] play
a pivotal role in asthma. We and others have showed that
IL-5 transcripts are detectable in the lungs of patients with
asthma, dominantly derived from the T cell fraction [4,5].
IL-5 is pivotal to eosinophil activation and survival. The
basic driving process in allergic asthma is the class switch-
ing to and secretion of IgE by B lymphocytes, in response
to cytokines such as IL-4. This defines the atopic pheno-
type. IgE to environmental allergens (referred to as spe-
cific antibody) binds to the respective allergen with high
affinity. The allergen interacts with IgE on the surface of
human mast cells, and mediates signaling via the high
affinity IgE receptor (FcεR1) (Figure 1). FcεR1 aggregation
is followed by mast cell activation and degranulation.
Mast cells release a plethora of mediators (Figures 1 and 2
and Table 1) which can, in turn, regulate eosinophil acti-
vation [6,7], Th2 skewing and B cell class switching to IgE
[8,9]. Mast cells can also be activated by IgE-independent
mechanisms such as bacterial infection [10], toll-like
receptors, IL-1 [11] and by contact with either T cells [12]
or fibroblasts [13]. IgE-mediated inflammatory responses
may be responsible for a variety of atopic disorders,
including rhinitis, asthma, eczema, food allergy, otitis
media, anaphylaxis and asthma. Figure 2 demonstrates
the pivotal position of IgE and mast cells in the initiation
of the asthma inflammatory cascade. Mast cells (1) can
interact with B cells (2) which can both interact with Th2
type T cells (3), an interaction mediated by cell surface
cognate molecules and resulting in IgE class switching in
B cells and cytokine expression. This can lead to endothe-
lial activation (4), allowing the emigration of activated
eosinophils (5) into airway tissue. Eosinophil-derived
products (including major basic protein, cytokines, chem-
okines, and leukotrienes) can influence airway remode-
ling by inducing changes in airway cells (6) such as
epithelium, fibroblasts and smooth muscles. Airway
inflammation and airway remodeling together result in
airway obstruction, which manifests clinically as dyspnea
and wheezing.
The dominant mechanism of mast cell activation remains
by IgE-antigen-FcεR1 interactions. Hence, inhibition of
this pathway is likely to modulate an early phase of aller-
gic inflammation. This concept led to the development of
an anti-IgE antibody (omalizumab) as a treatment option
Table 1: Asthma Definitions
Manifestation Definition
Asthma Inflammatory disease of the airways characterized by:
• Infiltration by eosinophils, lymphocytes and neutrophils
￿ Mast cell activation
￿ Epithelial loss
Associated reversible airway obstruction, recurrent symptoms and bronchial hyper-responsiveness
Gene-by-environment interactions are important
Inflammation Plays central role in asthma pathophysiology
Mediated by T cells, lymphocytes, mast cells, eosinophils and epithelium. Other resident cells such as 
fibroblasts and smooth muscle play a role
Airway remodeling As inflammation proceeds, other changes evolve leading to reparative or remodeling changes and include:
￿ Sub-basement membrane thickening
￿ Subepithelial fibrosis
￿ Smooth muscle hypertrophy
￿ Angiogenesis
Mucus gland hyperplasia and hypersecretion
Bronchoconstriction Airway narrowing resulting in wheezing
Probably acutely due to release of mast cell mediators such as histamine, leukotrienes, and tryptase
Obstruction could be mediated by multiple factors:
￿ Smooth muscle contraction
￿ Airway edema
￿ Airway remodeling and fibrosis
Bronchial Hyperresponsiveness Exaggerated bronchoconstrictive response to a wide variety of stimuli; best measured clinically by 
methacholine challenge testing; mediated by inflammation, remodeling and other airway changes that occur 
in asthmaClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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for atopic diseases. The following sections will review the
structure and clinical use of omalizumab.
The problem
On the one hand, we are seeing an alarming increase in
asthma incidence, severity and mortality. On the other, in
spite of major advances in therapies, new delivery devices
and improved potency of medications (inhaled steroids,
long acting beta2-adrenergic agonists/LABA, combination
medications, leukotriene antagonists), asthma is still a
chronic and incurable disease. The major morbidity of
asthma is associated with frequent exacerbations, emer-
gency room visits, hospitalizations, and complications
associated with some of the therapies. Moreover, a signif-
icant number of cases are poorly controlled despite com-
bination therapy with high doses of inhaled
corticosteroids and long-acting β-agonists, leukotriene
antagonists and allergy immunotherapy. The GOAL study
demonstrated that 38–53% of patients using "optimal
therapy" continued to have poorly controlled disease
[14]. This suggests a need for alternative strategies and
agents. Such patients have additional comorbid problems
such as esophageal reflux, chronic sinusitis or severe sen-
sitivity to indoor inhalant allergens or pollutants, but con-
tinue to be symptomatic even when these factors are
evaluated and treated. Moreover, the risk for dying in
patients with severe asthma is fairly high, with a 6-fold
increased risk for dying 3 years after hospital discharge.
The new guidelines suggest that such patients with mod-
erate or severe persistent asthma (step 5 or 6) may be can-
didates for the use of omalizumab.
Omalizumab: historical and molecular aspects
The clinical applicability of anti-IgE products was concep-
tualized over 15 years ago [15-17], with a number of sub-
sequent trials demonstrating their safety in several allergic
conditions [18]. The idea for use in humans stemmed
from the development of a murine monoclonal antibody
termed MAE11, shown to block the interaction of IgE with
basophils or mast cells without leading to cross-linking or
degranulation. Multiple attempts were made to humanize
this antibody and it was version 25 of these experiments
which rendered a product with a profile similar to that of
MAE11 [19]. This recombinant humanized monoclonal
antibody was termed rhuMAb-E25, alternative names
including IgE 025, omalizumab, and Xolair™ (which is
how it is currently being marketed by Genentech/
Novartis, South San Francisco, CA, and Tanox, Inc., Hou-
ston, TX). It consists of 95% human IgG1 and 5% murine
IgG [20], a framework which reduced the potential for
immunogenicity [16,21]. Omalizumab targets the Cε3
epitope on the fragment of IgE which binds the α chain of
the high-affinity trimericthe IgE receptor (Figure 3), thus
blocking the binding of IgE with its receptor [22].
Omalizumab pharmacokinetics
Omalizumab is usually administered via the subcutane-
ous route, after which it will have a bioavailability of 62%
and reach its peak serum concentration within seven to
eight days [23]. Omalizumab has a long half-life (19 to 22
days), in part due to the slow removal by the hepatic retic-
uloendothelial system conferred by the IgG1 portion [24].
Availability of IgE and the receptor to which it is bound
(low- or high-affinity) dictate the clinical effects of anti-
Table 2: Inflammatory events in asthma: Role of Cytokine-IgE Axis and Inflammatory Cells
Event Cell types involved Mediators Cell type affected Net effect
Inflammation Antigen-presenting cell CSM T cells, B cells T cell activation Antibody synthesis
TNF alpha Endothelium Cell adhesion, recruitment
Mast cells IL-4 T cells Th2 cell polarization
IL-4, IL-13 B cells IgE class switching
IL-13 Goblet cell Mucus secretion CAM
TNF-alpha Endothelium upregulation
LTs Smooth muscles Contraction
LTs, IL-5 Eosinophils Chemoattraction, survival
Histamine Endothelium etc Edema, bronchospasm
T cells IL-4, IL-13 B cells IgE class switching
IL-5 Eosinophils Hematopoiesis, survival
IL-9 Mast cells BHR, mast cell growth
B cells IgE Mast cells, 
basophil
Early phase
response
Mediator release
Eosinophil MBP Epithelium, mast cells Injury, histamine release
LTs Smooth muscle Contraction
Cytokines Multiple types Inflammation
CSM = Costimulatory molecule; LTs = leukotrienes; MBP = Major Basic Protein of Eosinophil; BHR = Bronchial hyperresponsivenessClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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IgE therapy, explaining a potential delay of weeks before
any appreciable activity is noted [25]. The efficacy of oma-
lizumab does not appear to differ when given subcutane-
ously or intravenously [26], with both routes causing a
dramatic decrease in IgE levels. In spite of this, there may
be more to explaining the mechanisms of omalizumab, as
very few IgE molecules on a mast cell or basophil are
required to cause sensitization [27]. With regards to other
potential forms of administering the product, the study by
Fahy et al. utilizing aerosolized E25 in allergic patients
failed to demonstrate a significant decrease in serum IgE
levels or any appreciable advantage over placebo in amel-
iorating early phase response, despite reporting the pres-
ence of anti-IgE in blood [28]. In addition, it appears this
route is more immunogenic, as IgG and IgA antibodies to
E25 were detected in one patient.
Molecular structure and interactions with IgE
Omalizumab acts by selectively binding free IgE mole-
cules (Figure 3), consequently disabling their interaction
with the heavy chain FcεRI [29]. With IgE-mediated anti-
gen cross-linking being inhibited, there will be no activa-
 The allergen interacts with IgE on the surface of human mast cells, and  mediates signaling via the high affinity IgE receptor  (FcεR1) Figure 1
 The allergen interacts with IgE on the surface of human mast cells, and   mediates signaling via the high affinity IgE recep-
tor (FcεR1). FcεR1 aggregation is followed by   mast cell activation and degranulation.   Mast cells release a plethora of 
mediators which can then regulate eosinophil activation, Th2 skewing and B cell class switching to IgE. This sequence of events 
ultimatelyresults in   a number of immunologic and inflammatory responses.
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tion of mast cells or basophils [30]. This mechanism is
made possible by the spatial arrangement of the Fc of IgE,
composed of two heavy chains with binding sites for
FcεRI, FcεRII (CD23), and anti-IgE symmetrically posi-
tioned along a central rotational axis through its two CH3
domains [31]. These three binding sites happen to be sit-
uated in an overlapping manner, hence occupation of one
of these sites precludes any of the other two from addi-
tional interactions due to conformational changes
[32,33]. Also, when there is binding of FcεRI to one CH3
domain, this inhibits anti-IgE from interacting with its
antigenic site on the other CH3 domain. Interestingly,
there may be attachment of anti-IgE to both CH3
domains, probably because this interaction does not lead
to a significant change in conformation [31].
The affinity of anti-IgE for IgE is about 10-10 M, which is
comparable to that between FcεRI and IgE [31,34]. Oma-
lizumab leads to a reversible decrease in the unbound
serum IgE of 84–99% within approximately 1 hour, with
low levels lasting 4–6 weeks after a single subcutaneous
injection [23,35]. This is extremely significant, as expres-
This figure demonstrates the pivotal position of IgE and mast cells in the initiation of the asthma inflammatory cascade Figure 2
This figure demonstrates the pivotal position of IgE and mast cells in the initiation of the asthma inflammatory cascade. Mast 
cells   can interact with B cells   which can both interact with Th2 type T cells  , an interaction mediated by cell surface 
cognate molecules and resulting in IgE class switching in B cells and cytokine expression. This can lead to endothelial activation 
 allowing the emigration of activated eosinophils   into airway tissue. Eosinophil-derived products (including major basic 
protein, cytokines, chemokines, and leukotrienes) can influence airway remodeling by inducing changes in airway cells   such 
as epithelium, fibroblasts and smooth muscles.
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sion of FcεRI is directly influenced by IgE levels, with the
use of omalizumab down-regulating this receptor on the
surface of basophils, dendritic cells (types 1 and 2), and
skin mast cells (at a slower rate) [21,36-38]. This effect on
dendritic cells will consequently disturb normal IgE-facil-
itated presentation of antigens to T cells. The use of oma-
lizumab will cause a progressive dissociation of IgE from
basophils extending over 3–4 weeks [39]. As FcεRI
becomes free from IgE on the surface of mast cells and
basophils, the receptors will suffer engulfment and degra-
dation, with a similar process occurring to the newly-
formed FcεRI molecules which never interact with IgE
[31]. These events result in desensitization of both mast
cells and basophils, leading to a much higher antigenic
requirement to trigger an atopic reaction [37,40].
As mentioned, omalizumab is nonimmunogenic thanks
to a specific property inherent to the product, which is a
lack of interaction with IgE molecules already complexed
with FcεRI or FcεRII, avoiding histamine release and
potential anaphylactic reactions [16,31]. Anti-IgE does
however interact with mIgE (membrane-bound IgE) on
the surface of B cells which express this molecule, with
subsequent cell lysis or inhibition [31].
As the IgE molecules become free from FcεRI, they will be
bound by anti-IgE molecules circulating close by, forming
immune complexes (Figure 3) which will provide addi-
tional protection by attaching to new incoming allergens
and impede their binding to other FcεRI molecules
[18,31]. The omalizumab-IgE immune complexes have
not been shown to cause tissue damage or to fix comple-
ment, mainly due to their small size (the molecular
weight is less than 1,000 kDa) and to the fact that there is
very little accumulation of the complexes (the main route
of excretion is urinary), even in the face of very high levels
of IgE [19,41]. There may be local accumulation of
immune complexes in the extravascular space (such as the
mucosal epithelial lining), as anti-IgE can cross capillaries
but is not able to return once complexed with IgE, and
may therefore contribute to local protection against aller-
gens [31]. The level of total IgE is actually elevated during
use of omalizumab (as this assay includes the IgE-omali-
zumab complexes, which are cleared at a slower rate than
IgE), while in reality free IgE is decreased [42].
Molecular and clinical effects
As shown in Table 3, use of omalizumab has been evalu-
ated in several allergic conditions, including allergic rhin-
itis, asthma, Churg-Strauss syndrome, atopic eczema,
urticaria, angioedema, latex allergy, and concurrently with
allergy immunotherapy to try to blunt reactions. While
approved by the Food and Drug Administration (FDA) for
asthma, the other indications need to be studied further.
These will be reviewed later.
One of the main focus points of recent trials has been the
use of omalizumab in asthma. Table 4 lists the molecular
and clinical effects of omalizumab in asthma. Researchers
have analyzed both direct and indirect effects of the bio-
logical agent. Direct effects include decreased free level of
IgE and decreased FcεRI expression on mast cells and
basophils. Indirect effects are probably mediated by
effects of mast cell activation and IgE regulation. These
include decreased tissue levels of eosinophils, mast cells,
T cells and B cells [43]. Omalizumab has been postulated
to have a mast cell "stabilizing" effect [29].
By way of its inhibition of several key mediators outlined
in Figures 1 and 2 (e.g. proinflammatory cytokines,
Table 3: Conditions shown to respond to omalizumab/anti-IgE* 
therapy
Condition Reference
Allergic rhinitis [66,69,85-89]
Allergic asthma:
￿ Moderate-severe persistent disease [55,64,90-94]
￿ Steroid-sparing effect [57,95,96]
Churg-Strauss syndrome [97,98]
Peanut anaphylaxis* [52,70,71,99,100]
Uticaria [78]
Angioedema [101]
Immunotherapy reactions [102]
Rubber latex allergy [79]
Omalizumab targets the Cε3 epitope on the fragment of IgE  which binds the α chain of the high-affinity trimeric IgE  receptor, thus blocking the binding of IgE with its receptor Figure 3
Omalizumab targets the Cε3 epitope on the fragment of IgE 
which binds the α chain of the high-affinity trimeric IgE 
receptor, thus blocking the binding of IgE with its receptor. 
On the left, formation of a hexamer complex of omalizumab-
IgE is shown, and on the right molecular sizes of the IgE and 
Omalizumab molecules are shown.Clinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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growth factor, nitric oxide), omalizumab significantly
affects both early and late phases of asthma [23,44],
diminishing the frequency of exacerbations and the need
for inhaled steroids [45,46]. The late phase response is
dependent on the influx and activation of granulocytes,
and omalizumab acts by decreasing the number of eosi-
nophils in sputum, blood, and nasal mucosa, achieved
through inhibition of IL-5 secretion by mast cells and
basophils and by directly inducing apoptosis of eosi-
nophils [25,47-50]. Another beneficial effect is the
decrease in airway responsiveness to adenosine 5'-mono-
phosphate (a marker of airway inflammation in allergic
asthma) seen with omalizumab use [51]. It needs to be
understood that the early and late phase responses are
experimental constructs and efficacy in these responses
may not necessarily represent improvement in clinical
asthma, which is best determined by improvements in
quality of life measures, lung function, peak expiratory
flow rates, and hospitalization or medication use. Never-
theless, the early and late phase responses provide one
measure of studying drug efficacy in airway inflammatory
disease.
The clinical effects on asthma are summarized in Table 4
and include improved asthma scores, decreased exacerba-
tions, decreased steroid use, improved peak flows,
decreased hospitalizations, and improved asthma control
[52,53]. Several studies have demonstrated that adminis-
tration of omalizumab is associated with a decreased inci-
dence of exacerbations in asthma. Selected studies and
reviews are listed in Table 3. Milgrom and colleagues eval-
uated high- and low-dose omalizumab (rhuMAbE25) in a
placebo-controlled study of patients with asthma requir-
ing inhaled or oral corticosteroids [54]. After a 4-week
run-in period, 317 patients were randomly assigned to
receive either placebo or high-dose (5.8 μg/Kg body
weight per nanogram of IgE) or low-dose omalizumab
(2.5 μg/Kg per nanogram of IgE) administered intrave-
nously. For the first 12 weeks of the study, subjects were
allowed to continue their regular doses of corticosteroids,
while in the subsequent 8 weeks, the doses of corticoster-
oids were tapered, in an attempt to discontinue therapy.
The investigators demonstrated lower asthma symptom
scores in the treatment groups. More subjects in the anti-
IgE group were able to lower doses or completely come off
corticosteroids [54]. The INNOVATE study [46] was a
double-blind, multicenter, parallel-group study of
patients with asthma in which patients were randomized
to receive omalizumab or placebo for 28 weeks. At the end
of the 28 weeks, patients receiving omalizumab had a
26% reduction in clinically significant exacerbations, 50%
reduction in numbers of severe exacerbations and a 44%
reduction in emergency room visits [46] compared to pla-
cebo. The omalizumab-treated patients also experienced
less hospitalizations, improved asthma scores, and greater
improvements in peak expiratory flows and pulmonary
Table 4: Presumed mechanisms of action of Omalizumab and effects in asthma
Immunological Effects
Direct effects Binding to constant region of IgE
Decreased free levels of IgE
Decreased mast cell/basophil FcεR1 expression
Indirect effects Decreased mucosal eosinophils
Decreased sputum eosinophils
Decreased tissue IgE+ mast cells
Decreased tissue B and T lymphocytes
Inhibition of early and late phase reactions
Improved BHR/unchanged BHR
Improved response to methacholine challenge
Mast cell stabilization: inhibits degranulation
Clinical Effects
Effects on asthma Decreased exacerbations
Improved peak flow
Small improvement in FEV1
Decreased rescue β2-agonist use
Improved quality of life
Decreased mean nocturnal clinical score
Decreased total asthma clinical score
Decreased hospitalizations
Improved asthma control
Steroid-sparing effectClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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functions. Such effects on exacerbations were also
observed in several other studies of severe or moderate-
severe persistent asthma [55-65]. In a meta-analysis, Hol-
gate [65] demonstrated that omalizumab administration
in severe asthma halved the rate of exacerbations and
improved quality of life parameters.
Effects of omalizumab in non-asthma conditions
The use of omalizumab has been successful in patients
with both perennial [66] and seasonal rhinitis [26,67], in
addition to a demonstrable benefit in patients with both
allergic rhinitis and asthma [68]. The documented advan-
tages include an improvement in overall quality of life, a
decrease in the use of rescue antihistamine therapy, and
fewer nasal symptoms [69]. The one caveat with regards to
seasonal rhinitis is that the efficacy of omalizumab has
only been shown to occur with doses capable of suppress-
ing IgE levels to < 25 ng/ml [26,35,67].
A trial conducted with another monoclonal anti-IgE
(TNX-901) reported an increase in the threshold for pea-
nut sensitivity, signifying a potentially protective effect
against severe adverse reactions deriving from uninten-
tional ingestion [70]. A phase II trial with similar charac-
teristics was initiated with omalizumab but put to a halt
owing to reports of serious reactions to peanut flour in
some patients before they received omalizumab [71]. Irre-
spective of this setback, further studies are planned for the
near future [72].
Omalizumab has been used with a positive outcome in
several small studies of urticaria. In the skin, omalizumab
has a predominant influence on the late phase response,
mainly due to the more rapid uncoupling of IgE from its
low-affinity CD23 receptors (directly involved in the late
phase) when compared to the high-affinity FcεRI [73].
Many studies have highlighted the positive effect of oma-
lizumab on atopic dermatitis, especially in patients with
moderately elevated IgE levels [74-76], but at least one
study has documented failure of this treatment (the
patients had very high levels of IgE) [77]. Despite this, IgE
levels did not factor in the efficacy of omalizumab in
patients with chronic urticaria, with a positive outcome
observed with levels ranging from low to very high [78].
In addition, other studies have demonstrated a positive
effect in alleviating symptoms in patients with latex
allergy and in the treatment of cold-induced urticaria
[79,80].
Omalizumab: adverse events and safety
Tables 5 and 6 summarize the adverse effects seen to date
with omalizumab. Of these, three events are probably
important and need to be discussed. Local reactions occur
fairly frequently in patients receiving omalizumab injec-
tions. These usually manifest as bruising, warmth, ery-
thema, swelling, urticaria-like eruption. The local
reactions are sometimes severe (in up to 12% injections).
Anaphylaxis can occur in about 0.1% of injections. As
reviewed by the American Academy Of Allergy, Asthma
and Immunology and the American College of Allergy,
Asthma and Immunology Joint Task Force Report [81], 35
patients had 41 episodes of anaphylaxis associated with
omalizumab, corresponding to an anaphylaxis-reporting
rate of 0.09% of patients. Of these 36 events for which
time of reaction was known, 22 (61%) of the reactions
occurred in the first 2 hours after injection, usually after
one of the first three doses. The Task Force concluded that
Table 6: Omalizumab-Other features
Drug interactions Unknown
Pregnancy Category B
Nursing Excreted in milk*
Fertility Study with monkeys shows no effect
Pediatric use Safety below 12 years unknown
Geriatric use Not enough data
* No human data available
Table 5: Adverse events with Omalizumab
System Reaction/AE Frequency Other aspects
Systemic Malignancy 20/4127 patients 0.5% versus 0.2% control Breast, prostate, melanoma Skin cancer, parotid, etc.
Anaphylaxis 1/1000 patients 0.1%–0.2% 60% within 1–3rd dose <2 hrs 14% after 4th dose, <30 mins
Viral infection 23% Fever, myalgia, etc. 53% versus 42% control
Parasitic infection 36/68 Odds risk 1.98 Geohelminths
Immunogenicity <0.1% Antibody to Omalizumab
Cutaneous Injection site reaction 45% Warmth, erythema Bruising, burning
Skin eruption* 6% Dermatitis, urticaria
Respiratory Infections* 20%
Sinus Sinusitis* 15%
CNS Headache* 15%
Pharynx Pharyngitis* 11%
Platelets Thrombocytopenia ? Post-marketing observation
Integument Alopecia ? Post-marketing observation
* Reactions occurring at the same rate as placebo/controlsClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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an observation time of 2 hours for the first three injections
and 30 minutes after that would have captured 75% of the
reactions [81]. That still leaves 25% of reactions that could
pose a risk but the combination of anaphylaxis education,
provision of an epinephrine auto–injector and close mon-
itoring should be effective in averting or treating anaphy-
laxis, should that occur. Anaphylaxis management is
discussed in Table 7 and administration of Epipen auto–
injector is demonstrated in Figure 4. Finally, initial studies
showed a small increase in the numbers of malignancies
in the treated individuals. Out of 4127 omalizumab-
treated patients, 20 cases of malignancy appeared. These
included breast, prostate, melanoma, and parotid tumors.
One case of lymphoma was recorded. Initial data sug-
gested that these malignancies occurred in 0.5% of omal-
izumab-treated patients compared to 0.2% of controls. A
later review of that data by an independent review group
and comparisons with the SEER database of cancer inci-
dence suggested that the incidence with omalizumab was
no different from that of the general population. Cur-
rently under way is the EXCEL trial, a long-term prospec-
tive study which addresses the specific issue of the risk of
cancer associated with omalizumab therapy.
Interestingly, no cases of serum sickness or anti-omalizu-
mab monoclonal antibodies have been recorded to date,
although Dreyfuss and Randolph described one case of
anaphylactoid reaction to omalizumab which evolved
later into a serum sickness-like syndrome after pretreat-
ment with a nonsteroidal agent [82]. This required dis-
continuation of the medication. Omalizumab is
pregnancy category B and is excreted in milk (Table 6).
Insurance and reimbursement issues
The use of omalizumab was first approved in the United
States in 2003 and in Europe in 2005 [30]. In the U.S.,
Apart from certain particularities which may vary accord-
ing to region, most issues (i.e. reimbursement, preauthor-
ization, continued coverage) have been standardized [83].
Insurance companies may differ with regards to copay-
ment and deductible specifications.
In order for a prescription of omalizumab to be filled, a
participating specialty pharmacy will require a "statement
of medical necessity" (SMN). This document will include
the diagnosis of allergic asthma, a list of current medica-
tions, the patient's serum IgE level, and the positive results
of the allergy testing performed. The pharmacy will then
proceed to contact the patient's insurance company and
determine if coverage is provided.
Administration of Epipen autoinjector Figure 4
Administration of Epipen auto–injector. Panel 1 shows an 
auto–injector, and panels 2–4 demonstrate steps in arming 
the autoinjector and self-administration technique. The 
patient should grip the unit with the black tip pointing down-
ward (panel 2) and proceed to pull off the gray safety release 
(panel 3). The injector should then be applied at a 90° angle 
with the outer thigh and held firmly for approximately 10 
seconds after a click is heard (panel 4).
Table 7: Anaphylaxis management
Immediate treatment Assessment of breathing, circulation and orientation
Inject epinephrine 0.3 mg intramuscularly in lateral thigh
Activate emergency services (911)
Patient to be placed in recumbent position
Establish and maintain airway Oxygen
Establish an intravenous line
Use nebulized beta-agonist for bronchospasm +/- corticosteroids and antihistamines
Long-term prevention Patient education
Provision of epinephrine autoinjector
Anaphylaxis identification (card, bracelet)
Xolair information sheetClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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In the event of a claim denial, Genentech has set up a Sin-
gle Point of Contact (SPOC) program which offers serv-
ices such as benefit investigations and appeals assistance
free of charge, apart from assisting patients in obtaining
reimbursement for their products. If the patient does not
have insurance or has been rejected for insurance and
meets certain financial criteria, this program may provide
medications free or at a reduced rate.
Even when approval for omalizumab use is given, it is
usually only for a period of six months. Most insurance
companies will then require a "recertification of contin-
ued use" to establish if the medication is truly providing
any benefit. Documentation must be provided by the phy-
sician that there has been an improvement in symptoms
or a reduced frequency of exacerbations, usually at six and
twelve months after omalizumab has been started. The
physician may also opt to document improvement via
pulmonary function testing. Of note, the efficacy of oma-
lizumab is determined after a minimum treatment period
of twelve weeks, due to the delay in onset (as specified
above).
Indications for omalizumab
Some criteria for approval of use that have become virtu-
ally universal across insurance plans include: (1) a diag-
nosis of moderate to severe persistent asthma, (2) age ≥ 12
years, (3) serum IgE levels between 30 and 700 IU/ml,
and (4) a positive skin test or blood test (such as radioal-
lergosorbent test – RAST) for at least one perennial aeroal-
lergen. The recent asthma guidelines [1] recommend the
use of omalizumab for moderate to severe persistent
asthma (steps 5 and 6) specifically.
Additional criteria, such as need for pre-bronchodilator
FEV1 within the past six months, negative current smok-
ing status, use of high-dose inhaled steroids for at least six
weeks (usually in association with a long-acting bron-
chodilator and leukotriene modifier), and presence of
active symptoms (i.e. daily use of bronchodilators/con-
stant need for rescue therapy, asthma-related hospitaliza-
tion within the past twelve months) have been variably
used.
It is important to note that omalizumab will not be
approved for treatment of asthma exacerbations (acute
bronchospasm or status asthmaticus). Allergic rhinitis is
not considered an indication for omalizumab use and will
not usually be covered by insurance carriers. However,
when used in patients with asthma and concurrent rhini-
tis, omalizumab is likely to be effective in controlling
upper airway symptoms. Omalizumab is currently
approved for use in adults and children over 12 years of
age; studies are ongoing for children under the age of 12.
The acceptable codes for reimbursement (according to the
Ninth Revision of the International Classification of Dis-
ease – ICD-9) are 493.00, 493.1, 493.9. The current pro-
cedural terminology (CPT) code for omalizumab use is
90772 and can be billed for each given injection. The CPT
codes for percutaneous skin testing are 95024, 95028,
95004. In addition to the CPT code, there is a J code appli-
cable for omalizumab, which is J2357, utilized when the
medication is given in the office setting. The HCPC code
for therapeutic, prophylactic, or diagnostic injections of
omalizumab is 90772. HCPC codes describing chemo-
therapy injections are not to be used.
Omalizumab dosing and duration of therapy
Omalizumab dose is calculated based on the patient's
baseline serum IgE and the patient's body weight. The
decision on the dose and frequency of administration can
be made using the standardized tables (Tables 8 and 9).
The dosage of omalizumab chosen is calculated to result
in neutralization of free IgE to levels < 5% at baseline
(0.016 mg/kg of omalizumab per IU/mL per 4 weeks).
The total IgE may actually increase secondary to forma-
tion of omalizumab-IgE complexes and hence the IgE lev-
els should not be measured after treatment initiation. The
patient needs to understand that this is a long-term ther-
apy, administered subcutaneously every 2 or 4 weeks
depending on body weight and baseline IgE level [83].
Table 8: Administration every 4 weeks
Pre-treatment Body weight (Kg)
Serum IgE Level (IU/mL) 30–60 >60–70 >70–90 >90–150
>30–100 150 150 150 300
>100–200 300 300 300
>200–300 300
>300–400*
>400–500*
>500–600*
* See Table 8 for details on dosingClinical and Molecular Allergy 2008, 6:4 http://www.clinicalmolecularallergy.com/content/6/1/4
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Each vial of omalizumab contains 150 mg of the drug.
After reconstitution with 1.4 mL of sterile water for injec-
tion, the vial will contain 150 mg of omalizumab in 1.2
mL of liquid. Swirling is necessary to accomplish com-
plete solution of the medication, which is then adminis-
tered subcutaneously. Two caveats about administration
exist, namely that the total dose cannot exceed 375 mg
and the dose/single injection should not exceed 150 mg,
resulting in the need sometimes for multiple injections.
Observation for anaphylactic events is required as dis-
cussed under the adverse events section. The cost per vial
of omalizumab is $470, and depending on dosages, the
cost/year may vary between $6000 and $36000 [83]. A
recent study by Wu et al. assessed the cost-effectiveness of
omalizumab in the treatment of asthmatic patients [84].
They found that the costs amount to $821,000 per qual-
ity-adjusted life year (QALY) and $120 for each symptom-
free day gained. They go on to conclude that omalizumab
therapy is only cost-effective in seriously ill asthmatics
failing to achieve adequate control with other treatment
modalities.
Conclusion
There are several unmet needs in asthma. Severe asthma is
a difficult disease to control and is associated with signif-
icant morbidity and mortality. Omalizumab, a human-
ized monoclonal antibody, has been shown to be effective
in difficult-to-control asthma. Further studies are required
to determine which patients may most benefit from oma-
lizumab.
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